Literature DB >> 36118402

A Series of Primary Signet Ring Cell Carcinoma of the Urinary Bladder.

B Nerli Rajendra1, Nitin D Pingale1, Shridhar C Ghagane2, Ameya T Wagh1, Prakah R Malur3.   

Abstract

Primary signet ring cell carcinomas of the bladder (PSRCCB) are extremely rare tumors. These tumors generally present as high-grade, high-stage tumors and have a uniformly poor prognosis. PSRCCB need to be differentiated from metastases from other primary sites. Clinical, imaging, and immune-histochemical findings may help in identifying the primary source of signet cell cancer. We retrospectively reviewed our series of patient identified to have primary signet cell carcinoma of the bladder. We retrospectively reviewed all case records of patients with carcinoma bladder. Only patients with a histopathological report of signet ring cell carcinoma of the bladder were included in this study. During the period Sept 1991 to Aug 2016, a total five patients (0.18%) were diagnosed to have had PSRCCB. Hematuria was the main symptom in four of the five patients. Cystoscopy/TURBT was done in all patients, and histological examination confirmed signet cell carcinoma. All the patients were counseled and underwent radical cystectomy. The mean overall survival was 28.2 ± 3.7 months. We report a small series of primary signet cell carcinoma presenting over a 25-year period with an overall incidence of 0.18%. Post radical cystectomy local recurrence/distant metastases are common and response to chemotherapy was poor. The overall outcome for signet-ring cell cancers in general is very poor. © Indian Association of Surgical Oncology 2017.

Entities:  

Keywords:  Adenocarcinoma; Carcinoma; Signet ring cell; Urinary bladder

Year:  2017        PMID: 36118402      PMCID: PMC9478071          DOI: 10.1007/s13193-017-0664-z

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  11 in total

1.  Signet-ring cell carcinoma of the urinary bladder.

Authors:  O SAPHIR
Journal:  Am J Pathol       Date:  1955 Mar-Apr       Impact factor: 4.307

2.  Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature.

Authors:  Jorg Michels; Sean Barbour; Douglas Cavers; Kim N Chi
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  A study of 52 cases of adenocarcinoma of the bladder.

Authors:  D G Thomas; A M Ward; J L Williams
Journal:  Br J Urol       Date:  1971-02

4.  Primary signet ring cell carcinoma of the urinary bladder successfully treated with intra-arterial chemotherapy alone.

Authors:  Yasuhiro Hirano; Kazuo Suzuki; Kimio Fujita; Hiroshi Furuse; Ken Fukuta; Motoaki Kitagawa; Yoshio Aso
Journal:  Urology       Date:  2002-04       Impact factor: 2.649

5.  Signet-ring cell carcinoma arising from the urinary bladder.

Authors:  Imre Romics; Eszter Székely; Attila Szendroi
Journal:  Can J Urol       Date:  2008-10       Impact factor: 1.344

Review 6.  The global burden of urinary bladder cancer.

Authors:  D Maxwell Parkin
Journal:  Scand J Urol Nephrol Suppl       Date:  2008-09

Review 7.  [Transitional cell carcinoma of the urinary bladder accompanied by signet-ring cell carcinoma: a case report].

Authors:  Zen Ozeki; Shuichiro Kobayashi; Tatuya Machida; Kazuhiro Ishizaka; Teruaki Oka
Journal:  Hinyokika Kiyo       Date:  2003-07

Review 8.  Primary signet-ring cell carcinoma of the urinary bladder.

Authors:  Shusuke Akamatsu; Akira Takahashi; Masaaki Ito; Keiji Ogura
Journal:  Urology       Date:  2009-10-12       Impact factor: 2.649

9.  Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined s-1 and Cisplatin adjuvant chemotherapy.

Authors:  Takashi Hamakawa; Yoshiyuki Kojima; Taku Naiki; Yasue Kubota; Takahiro Yasui; Keiichi Tozawa; Yutaro Hayashi; Kenjiro Kohri
Journal:  Case Rep Urol       Date:  2013-05-08

10.  Primary Signet Ring Cell Adenocarcinoma of the Urinary Bladder: A Report of 2 Cases.

Authors:  Wiem Boukettaya; Jihene Feki; Slim Charfi; Nabil Toumi; Afef Khanfir; Tahia Boudawara; Jamel Daoud; Mounir Frikha
Journal:  Urol Case Rep       Date:  2014-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.